Lung bioavailability of hydrofluoroalkane fluticasone in young children when delivered by an antistatic chamber/mask

Journal of Pediatrics

Volumn 149, Issue 6, 2006, Pages 793-797

  Khan, Yasmeen ^a   Tang, Yufei ^a   Hochhaus, Guenther ^a   Shuster, Jonathan J ^a   Spencer, Terry ^a   Chesrown, Sarah ^a   Hendeles, Leslie ^a  

^a Department of Epidemiology and Health Policy Research ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AEROCHAMBER MAX; AEROCHAMBER PLUS; FLOVENT HFA; FLUORINATED HYDROCARBON; FLUTICASONE;

ANALYTIC METHOD; ARTICLE; ASTHMA; BIOAVAILABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIVERY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METERED DOSE INHALER; NEBULIZER; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; STEADY STATE;

ADMINISTRATION, INHALATION; ANDROSTADIENES; BIOLOGICAL AVAILABILITY; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; ELECTROSTATICS; FEMALE; HUMANS; HYDROCARBONS, FLUORINATED; INFANT; LUNG; MALE; MASKS;

EID: 33751418043     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2006.08.022     Document Type: Article

References (32)

1. Newman S.P. Spacer devices for metered dose inhalers. Clin Pharmacokinet 43 (2004) 349-360
2. Hendeles L., Hatton R.C., Coons T.J., and Carlson L. Automatic replacement of albuterol nebulizer therapy by metered-dose inhaler and valved holding chamber. Am J Health Syst Pharm 62 (2005) 1053-1061
3. Nielsen K.G., and Bisgaard H. The effect of inhaled budesonide on symptoms, lung function, and cold air and methacholine responsiveness in 2- to 5-year-old asthmatic children. Am J Respir Crit Care Med 162 (2000) 1500-1506
4. Bisgaard H., Gillies J., Groenewald M., and Maden C. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: a dose comparison study. Am J Respir Crit Care Med 160 (1999) 126-131
5. Teper A.M., Kofman C.D., Szulman G.A., Vidaurreta S.M., and Maffey A.F. Fluticasone improves pulmonary function in children under 2 years old with risk factors for asthma. Am J Respir Crit Care Med 171 (2005) 587-590
6. Sugerman R.W., Teper A.M., Girardi G., Scott C.A., Clements D.S., Wu W., et al. Fluticasone propionate HFA improves asthma control in pre-school age children with asthma [abstract]. J Allergy Clin Immunol 115 (2005) S4
7. Chavasse R.J., Bastian-Lee Y., Richter H., Hilliard T., and Seddon P. Persistent wheezing in infants with an atopic tendency responds to inhaled fluticasone. Arch Dis Child 85 (2001) 143-148
8. Bisgaard H., Anhøj J., Klug B., and Berg E. A non-electrostatic spacer for aerosol delivery. Arch Dis Child 73 (1995) 226-230
9. Anhøj J., Thorsson L., and Bisgaard H. Lung deposition of inhaled drugs increases with age. Am J Respir Crit Care Med 162 (2000) 1819-1822
10. Tal A., Golan H., Grauer N., Aviram M., Albin D., and Quastel M.R. Deposition pattern of radiolabeled salbutamol inhaled from a metered-dose inhaler by means of a spacer with mask in young children with airway obstruction. J Pediatr 128 (1996) 479-484
11. Janssens H.M., Devadason S.G., Hop W.C., LeSouëf P.N., De Jongste J.C., and Tiddens H.A. Variability of aerosol delivery via spacer devices in young asthmatic children in daily life. Eur Respir J 13 (1999) 787-791
12. Kenyon C.J., Thorsson L., Borgstrom L., and Newman S.P. The effects of static charge in spacer devices on glucocorticosteroid aerosol deposition in asthmatic patients. Eur Respir J 11 (1998) 606-610
13. Bessmertny O., Liang J., Hochhaus G., Chesrown S., and Hendeles L. Fluticasone plasma concentrations in children with asthma after delivery by MDI. J Pediatr Pharmacol Ther 6 (2001) 212-217
14. Liang J., Asmus M.J., Hochhaus G., Chesrown S., and Hendeles L. Differences in inhaled fluticasone bioavailability between holding chambers in children with asthma. Pharmacotherapy 22 (2002) 947-953
15. Asmus M.J., Hochhaus G., Tang Y., Chesrown S.E., and Hendeles L. Effect of MDI valved holding chamber antistatic coating on bioavailability of inhaled fluticasone in subjects with asthma [abstract]. Am J Respir Crit Care Med 169 (2004) A313
16. Brutsche M.H., Brutsche I.C., Munawar M., Langley S.J., Masterson C.M., Daley-Yates P.T., et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 356 (2000) 556-561
17. Falcoz C., Oliver R., McDowall J.E., Ventresca P., Bye A., and Daley-Yates P.T. Bioavailability of orally administered micronised fluticasone propionate. Clin Pharmacokinet 39 Suppl 1 (2000) 9-15
18. Dempsey O.J., Coutie W.J., Wilson A.M., Williams P., and Lipworth B.J. Evaluation of the buccal component of systemic absorption with inhaled fluticasone propionate. Thorax 54 (1999) 614-617
19. Peart J, Kulphaisal P, Orban JC. Relevance of electrostatics in respiratory drug delivery. Business Briefing: Pharmagenerics 2003;?:84-7. Available at http://www.touchbriefings.com/download.cfm?fileIDa285. Accessed January 10, 2006.
20. Rau J.L., Coppolo D.P., Nagel M., Avvakoumova V., Doyle C., Wiersema K., et al. The importance of non-electrostatic materials in holding chambers for delivery of HFA-albuterol. Respir Care 51 (2006) 503-510
21. Krishnaswami S., Möllmann H., Derendorf H., and Hochhaus G. A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma. J Pharm Biomed Anal 22 (2000) 123-129
22. Meibohm B., Hochhaus G., Möllmann H., Barth J., Wagner M., Krieg M., et al. A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids. J Pharmacokinet Biopharm 27 (1999) 127-147
23. Eid N., Morton R., Olds B., Clark P., Sheikh S., and Looney S. Decreased morning serum cortisol levels in children with asthma treated with inhaled fluticasone propionate. Pediatrics 109 (2002) 217-221
24. Visser M.J., van der Veer E., Postma D.S., Arends L.R., de Vries T.W., Brand P.L., et al. Side effects of fluticasone in asthmatic children: no effects after dose reduction. Eur Respir J 24 (2004) 420-425
25. Aronson N, Lefevre F, Piper M, Mark D, Bohn R, Speroff T, et al. Management of chronic asthma. Evidence Report/Technology Assessment 44. Agency for Healthcare Research and Quality Publication 01-E044, September 2001, p 5-6. Available at http://AHRQ.gov/clinic/epcsums/asthmasum.htm. Accessed January 19, 2006.
26. Todd G., Dunlop K., McNaboe J., Ryan M.F., Carson D., and Shields M.D. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet 348 (1996) 27-29
27. Amirav I., Mansour Y., Tiosano T., Chamny S., Chirurg S., Oren S., et al. Safety of inhaled corticosteroids delivered by plastic and metal spacers. Arch Dis Child 88 (2003) 527-528
28. Kunka R., Andrews S., Pimazzoni M., Callejas S., Ziviani L., Squassante L., et al. Dose proportionality of fluticasone propionate from hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs. Respir Med 94 Suppl B (2000) S10-S16
29. Harrison T.W., and Tattersfield A.E. Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax 58 (2003) 258-260
30. Möllmann H., Wagner M., Meibohm B., Hochhaus G., Barth J., Stöckmann R., et al. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol 53 (1998) 459-467
31. Whelan G.J., Blumer J.L., Martin R.J., Szefler S.J., and Asthma Clinical Research Network and the Pediatric Pharmacology Research Unit Network. Fluticasone propionate plasma concentration and systemic effect: effect of delivery device and duration of administration. J Allergy Clin Immunol 116 (2005) 525-530
32. Ahrens R., Lux C., Bahl T., and Han S.H. Choosing the metered-dose inhaler spacer or holding chamber that matches the patient's need: evidence that the specific drug being delivered is an important consideration. J Allergy Clin Immunol 96 (1995) 288-294